130 related articles for article (PubMed ID: 19238327)
1. Phase IB trial of oral talactoferrin in the treatment of patients with metastatic solid tumors.
Hayes TG; Falchook GS; Varadhachary A
Invest New Drugs; 2010 Apr; 28(2):156-62. PubMed ID: 19238327
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of oral talactoferrin alfa in refractory solid tumors.
Hayes TG; Falchook GF; Varadhachary GR; Smith DP; Davis LD; Dhingra HM; Hayes BP; Varadhachary A
Invest New Drugs; 2006 May; 24(3):233-40. PubMed ID: 16193240
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma.
Jonasch E; Stadler WM; Bukowski RM; Hayes TG; Varadhachary A; Malik R; Figlin RA; Srinivas S
Cancer; 2008 Jul; 113(1):72-7. PubMed ID: 18484647
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy.
Parikh PM; Vaid A; Advani SH; Digumarti R; Madhavan J; Nag S; Bapna A; Sekhon JS; Patil S; Ismail PM; Wang Y; Varadhachary A; Zhu J; Malik R
J Clin Oncol; 2011 Nov; 29(31):4129-36. PubMed ID: 21969509
[TBL] [Abstract][Full Text] [Related]
5. Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial).
Ramalingam S; Crawford J; Chang A; Manegold C; Perez-Soler R; Douillard JY; Thatcher N; Barlesi F; Owonikoko T; Wang Y; Pultar P; Zhu J; Malik R; Giaccone G;
Ann Oncol; 2013 Nov; 24(11):2875-80. PubMed ID: 24050956
[TBL] [Abstract][Full Text] [Related]
6. The role of talactoferrin alpha in the treatment of non-small cell lung cancer.
Kelly RJ; Giaccone G
Expert Opin Biol Ther; 2010 Sep; 10(9):1379-86. PubMed ID: 20684737
[TBL] [Abstract][Full Text] [Related]
7. Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
McBride D
ONS Connect; 2007 Jan; 22(1):14. PubMed ID: 17393636
[No Abstract] [Full Text] [Related]
8. Talactoferrin in Severe Sepsis: Results From the Phase II/III Oral tAlactoferrin in Severe sepsIS Trial.
Vincent JL; Marshall JC; Dellinger RP; Simonson SG; Guntupalli K; Levy MM; Singer M; Malik R;
Crit Care Med; 2015 Sep; 43(9):1832-8. PubMed ID: 26010687
[TBL] [Abstract][Full Text] [Related]
9. Effect of talactoferrin alfa on the immune system in adults with non-small cell lung cancer.
Madan RA; Tsang KY; Bilusic M; Vergati M; Poole DJ; Jochems C; Tucker JA; Schlom J; Giaccone G; Gulley JL
Oncologist; 2013; 18(7):821-2. PubMed ID: 23847257
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer.
Digumarti R; Wang Y; Raman G; Doval DC; Advani SH; Julka PK; Parikh PM; Patil S; Nag S; Madhavan J; Bapna A; Ranade AA; Varadhachary A; Malik R
J Thorac Oncol; 2011 Jun; 6(6):1098-103. PubMed ID: 21532506
[TBL] [Abstract][Full Text] [Related]
11. Talactoferrin immunotherapy in metastatic renal cell carcinoma: a case series of four long-term survivors.
Lewis MA; Hayes TG
J Clin Med Res; 2011 Feb; 3(1):47-51. PubMed ID: 22043271
[TBL] [Abstract][Full Text] [Related]
12. Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
Burris HA; Infante JR; Ansell SM; Nemunaitis JJ; Weiss GR; Villalobos VM; Sikic BI; Taylor MH; Northfelt DW; Carson WE; Hawthorne TR; Davis TA; Yellin MJ; Keler T; Bullock T
J Clin Oncol; 2017 Jun; 35(18):2028-2036. PubMed ID: 28463630
[TBL] [Abstract][Full Text] [Related]
13. Talactoferrin alfa, a recombinant human lactoferrin promotes healing of diabetic neuropathic ulcers: a phase 1/2 clinical study.
Lyons TE; Miller MS; Serena T; Sheehan P; Lavery L; Kirsner RS; Armstrong DG; Reese A; Yankee EW; Veves A
Am J Surg; 2007 Jan; 193(1):49-54. PubMed ID: 17188087
[TBL] [Abstract][Full Text] [Related]
14. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis.
Guntupalli K; Dean N; Morris PE; Bandi V; Margolis B; Rivers E; Levy M; Lodato RF; Ismail PM; Reese A; Schaumberg JP; Malik R; Dellinger RP;
Crit Care Med; 2013 Mar; 41(3):706-16. PubMed ID: 23425819
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study.
Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J
J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027
[TBL] [Abstract][Full Text] [Related]
16. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.
Bukowski R; Ernstoff MS; Gore ME; Nemunaitis JJ; Amato R; Gupta SK; Tendler CL
J Clin Oncol; 2002 Sep; 20(18):3841-9. PubMed ID: 12228203
[TBL] [Abstract][Full Text] [Related]
17. Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Schuler M; Cho BC; Sayehli CM; Navarro A; Soo RA; Richly H; Cassier PA; Tai D; Penel N; Nogova L; Park SH; Schostak M; Gajate P; Cathomas R; Rajagopalan P; Grevel J; Bender S; Boix O; Nogai H; Ocker M; Ellinghaus P; Joerger M
Lancet Oncol; 2019 Oct; 20(10):1454-1466. PubMed ID: 31405822
[TBL] [Abstract][Full Text] [Related]
18. An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma.
Choueiri TK; Michaelson MD; Posadas EM; Sonpavde GP; McDermott DF; Nixon AB; Liu Y; Yuan Z; Seon BK; Walsh M; Jivani MA; Adams BJ; Theuer CP
Oncologist; 2019 Feb; 24(2):202-210. PubMed ID: 30190302
[TBL] [Abstract][Full Text] [Related]
19. Renal Cell Carcinoma With Pulmonary Metastasis and Metachronous Non-Small Cell Lung Cancer.
Bowman IA; Pedrosa I; Kapur P; Brugarolas J
Clin Genitourin Cancer; 2017 Aug; 15(4):e675-e680. PubMed ID: 28258962
[TBL] [Abstract][Full Text] [Related]
20. Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Herbst RS
Semin Oncol; 2003 Feb; 30(1 Suppl 1):30-8. PubMed ID: 12644982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
